Skip to content
Guess what? Valuesider just got better: smarter and more intuitive.
CVS Health Corp

CVS

CVS Health Corp

CVS Health Corp historical holders

total: 19

Dodge & Cox Stock Fund CVS Health Corp transactions over time

Total transactions:
19
New positions:
1
Added:
11
Reduced:
7
Held since:
2019 Q3
Held for:
27 quarters
Latest activity:
2026 Q1
Dodge & Cox Stock Fund has been an institutional investor in CVS Health Corp (CVS) since 2019 Q3. According to 2026 Q1 report, Dodge & Cox Stock Fund holds 33,887,094 shares with a market value of roughly $2.43B representing 2.12% of their equity portfolio. The fund/company first acquired CVS in 2019 Q3, initially purchasing about 12.04M shares. Since the initial investment, Dodge & Cox Stock Fund has made 18 more transactions in this position.

Does Dodge & Cox Stock Fund still hold CVS?

Yes, Dodge & Cox Stock Fund continues to hold CVS Health Corp (CVS). According to their 2026 Q1 report, they maintain a position of 33,887,094 shares valued at approximately $2.43B, representing 2.12% of their equity portfolio.

When did Dodge & Cox Stock Fund first invest in CVS?

Dodge & Cox Stock Fund first invested in CVS Health Corp (CVS) in 2019 Q3 at the reported quarter-end price of $63.07 per share, acquiring 12,041,500 shares in their initial purchase.

What is Dodge & Cox Stock Fund's average cost basis for CVS?

Based on historical transaction data, Dodge & Cox Stock Fund's estimated cost basis for CVS Health Corp (CVS) is approximately $65.11 per share. This represents their average reported price* across all buy transactions.

Estimated cost basis*

Weighted AVG buy price:
$65.11
Weighted AVG sell price:
$74.36

CVS transactions history by Dodge & Cox Stock Fund

19 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q1
2.12%
33,887,094
$71.82
$2,433,771,091
-19.30% (-8,104,110)
-0.49%
2025 Q4
2.79%
41,991,204
$79.36
$3,332,421,949
-12.92% (-6,231,690)
-0.41%
2025 Q1
2.87%
48,222,894
$67.75
$3,267,101,068
+4.73% (+2,179,594)
+0.13%
2024 Q4
1.85%
46,043,300
$44.89
$2,066,883,737
+9.16% (+3,864,600)
+0.16%
2024 Q3
2.29%
42,178,700
$62.88
$2,652,196,656
+2.29% (+946,200)
+0.05%
2024 Q2
2.23%
41,232,500
$59.06
$2,435,191,450
+49.70% (+13,688,600)
+0.74%
2024 Q1
2.00%
27,543,900
$79.76
$2,196,901,464
+34.59% (+7,078,900)
+0.52%
2023 Q4
1.60%
20,465,000
$78.96
$1,615,916,400
+11.58% (+2,123,900)
+0.17%
2023 Q3
1.39%
18,341,100
$69.82
$1,280,575,602
+71.03% (+7,617,500)
+0.58%
2023 Q2
0.80%
10,723,600
$69.13
$741,322,468
+19.17% (+1,725,100)
+0.13%
2022 Q4
0.95%
$93.19
-2.19% (-201,200)
2022 Q3
1.11%
$95.37
+0.19% (+17,000)
2022 Q2
1.00%
$92.66
-1.32% (-122,700)
2021 Q4
0.99%
$103.16
-4.43% (-431,000)
2021 Q1
0.90%
$75.23
+4.95% (+459,600)
2020 Q4
0.90%
$68.30
+3.31% (+297,600)
2020 Q2
0.97%
$64.97
-25.14% (-3,015,400)
2020 Q1
1.38%
$59.33
-0.39% (-46,900)
2019 Q3
1.10%
$63.07
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.